HPM Partners LLC Acquires Shares of 41,126 Gilead Sciences, Inc. (GILD)
HPM Partners LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 41,126 shares of the biopharmaceutical company’s stock, valued at approximately $2,793,000.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Hall Laurie J Trustee boosted its stake in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares in the last quarter. Cable Hill Partners LLC boosted its stake in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares in the last quarter. Dubuque Bank & Trust Co. boosted its stake in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares in the last quarter. Webster Bank N. A. boosted its stake in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares in the last quarter. Finally, Thomas J. Herzfeld Advisors Inc. purchased a new stake in Gilead Sciences during the fourth quarter valued at about $143,000. 74.06% of the stock is owned by institutional investors.
Shares of Gilead Sciences, Inc. (GILD) traded down 0.23% during midday trading on Tuesday, hitting $73.27. 7,903,279 shares of the stock were exchanged. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $82.10. The firm has a 50 day moving average of $70.60 and a 200-day moving average of $68.59. The stock has a market cap of $95.69 billion, a P/E ratio of 7.96 and a beta of 1.21.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same period in the prior year, the business posted $3.08 earnings per share. Equities research analysts anticipate that Gilead Sciences, Inc. will post $8.76 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s payout ratio is presently 22.58%.
COPYRIGHT VIOLATION WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/08/08/hpm-partners-llc-takes-position-in-gilead-sciences-inc-gild-updated-updated-updated.html.
Several research firms have issued reports on GILD. BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 2nd. BMO Capital Markets reiterated a “hold” rating and issued a $76.00 target price (up from $75.00) on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Cowen and Company reiterated an “outperform” rating and issued a $90.00 target price on shares of Gilead Sciences in a research note on Wednesday, July 5th. Morgan Stanley reiterated an “equal weight” rating on shares of Gilead Sciences in a research note on Tuesday, July 11th. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a $81.00 target price (up from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Eleven investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $80.31.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the transaction, the insider now directly owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the transaction, the executive vice president now owns 106,113 shares in the company, valued at $8,051,854.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 206,666 shares of company stock worth $15,223,184. Company insiders own 1.30% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.